Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02221310

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

Targeted immune therapy with gemtuzumab ozogamicin (Mylotarg) in combination with chemotherapy followed by allogeneic stem cell transplantation will be given to patients with high risk acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).

Status: 
Recruiting
Study Date: 
Tue, 11/01/2011 to Fri, 12/01/2017
Intervention: 
Drug: Gemtuzumab Ozogamicin Gemtuzumab Ozogamicin 7.5 mg/m^2/dose given IV over 2 hours once during conditioning Other Name: Mylotarg